INDUSTRY REVIEWS: IN-DEPTH ANALYSIS, ACTIONABLE INSIGHTS
Scientia Industry Reviews are presentation decks on healthcare and life sciences markets that are poised to grow.
We draw on our extensive industry experience and analytical expertise to identify market segments that present significant opportunities. We then develop quantifiable insights into the trends and technologies that are driving these markets and make them available to our clients via our Industry Reviews. These presentation decks allow our clients to confidently make better decisions regarding which markets to target, and how best to penetrate them.
Please see examples of our presentations below. Follow the 'more info' link after each excerpt to sign in and access the full database of Scientia Industry Reviews.
Note: We require the use of a professional email address for the registration process. If you have signed up and have not received an email, please check your SPAM folder, as the confirmation emails may have been flagged as SPAM. Thank you.
|
Healthcare Market in China: Opportunities and Barriers of a Developing Economy Date Released: Feb 16, 2010 Emerging economies offer tremendous potential for the healthcare industry. While the China healthcare market is expected to grow threefold by 2015, significant uncertainties exist over how to best approach it and what are the keys to succeed. Indeed, the Chinese market presents an additional level of complexities and a completely different cultural approach to health and wellness compared to mature markets such as the U.S. and Europe. These idiosyncrasies can turn into either significant barriers to entry, or potential opportunities. Scientia has significant insight into the Chinese healthcare market and access to many of the leading experts in the healthcare field. This study provides some of the insights from Scientia’s internal research including:
|
|
Strategic Review of Healthcare Information Technology: Opportunities and threats associated with accelerating HIT adoption Date Released: Nov 10, 2009 Accelerated adoption of Healthcare Information Technology (HIT) by healthcare providers poses a number of opportunities and threats for existing HIT players as well as adjacent industries, such as clinical diagnostics. The HIT space is growing relative to other healthcare markets, driven by an underlying need to optimize the use of various healthcare resources. Within HIT, solutions that enable providers to become “meaningful users of electronic health record technology” will outpace other HIT solutions driven by the recent American stimulus bill. Looking at the market from a global stand point, the report finds substantial opportunities in regions outside of the United States, including a rapidly expanding Chinese market. Finally, the report provides an overview of clinical decision support systems (CDSS), which are believed to have considerable impact on the standardization of various healthcare services. HIT companies, as well as players in adjacent markets, stand at a significant strategic inflection point as they seek to address the opportunities and avoid the threats presented in this review. |
|
The Evolving Cosmeceuticals Market: How science is changing the standards of personal care Date Released: Nov 4, 2009 Cosmeceuticals are personal care products that go beyond a cosmetic by offering an added health benefit. While brand owners have traditionally focused on the beautifying properties of such products, there has been a recent shift in their marketing message to highlight health and wellness claims. This is driven by consumers taking a more active and preventative approach to not only their appearance, but their overall lifestyle. Once confined to the premium market, technological advancements such as new sun screens and delivery systems have expanded this market by making cosmeceuticals more affordable and accessible. As a result, this is a growing area of interest within not only the personal care space, but the field of Health and Wellness as well. An understanding of the cosmeceuticals market will be critical for manufacturers and ingredient suppliers alike. This presentation provides an overview of the field, gives examples of finished cosmeceutical products as well as the ingredients used to make functional benefit claims. Also highlighted are key global trends affecting the market in the coming years. |
|
Strategic Growth Opportunities in Parenteral Drug Delivery: Where Will Healthcare Decentralization Drive Parenterals Next? Date Released: Oct 27, 2009 In part to control costs and increase patient compliance, today’s healthcare market is seeing continued development of specialized products and services for decentralized settings such as the physicians’ office or the home. This has resulted in a divergence of products within the parenteral drug delivery market, where some products are dedicated to ‘centralized’ settings and others to ‘decentralized’ settings (e.g. syringes and needles vs. auto injectors and injection pens). What is the extent of this divergence? How will it impact further product developments? What are the emerging threats and opportunities within these two product groups? These are some of the key questions raised, in this review of the parenteral drug delivery market. |
|
Cell Biology, Changing Research and Discovery: How the increasing need for biological relevance is driving growth Date Released: Oct 20, 2009 The cell biology market, which focuses on the analysis of the most fundamental unit of life, the cell, is the largest market within the ~$30 Bn Life Sciences Tools industry. With sustained academic funding in the major world economies and tightening purse strings in pharmaceutical/biotech research and development, the cell biology segment is undergoing significant change. This review focuses on two cell biology segments in particular: cell-based assays and flow cytometry. Cell-based assays provide biologically significant data on the effects of drugs and other compounds on individual cells and cellular systems. As a result, cell assays have become rapidly adopted for use within basic research and drug discovery, in industry and academia. Flow cytometry technology was originally developed in the 1970’s and is a staple at academic and industrial institutions. However, recent innovations improving the ease of use and expanded detection capabilities are making flow cytometry an attractive market. Scientia Advisors knowledge of cell biology and life sciences can help clients identify opportunities within these multifaceted markets. |
|
Rethinking Insulin: The Changing Diabetes Treatment Landscape Date Released: Oct 13, 2009 Diabetes is a global problem and a growing market. For the treatment of type 2 diabetes, incretin mimetics and insulins are generating increasing revenues as more drugs go generic. Therapies with advantages beyond glucose management, such as delaying the onset of diabetes or helping with co-morbid conditions, will be used earlier in treatment. Currently, insulin is the last resort for treating diabetes, used after all other options have been exhausted. However, with better clinical efficacy and economic advantages over other therapeutics, insulin is in a position to be used earlier in diabetes treatment; particularly in price-sensitive emerging economies, which are seeing a boom in diabetes population. How can players position their drugs earlier in the diabetes treatment paradigm? What opportunities are emerging in developing economies? What franchises are at risk as insulin use increases? These are some of the key questions addressed in this analysis of the diabetes therapeutic market. |
|
Strategic Opportunities in Vaccines: New Technologies that Will Drive Growth in a Consolidated Market Date Released: Oct 6, 2009 Vaccines, antigenic agents that stimulate the immune system to recognize disease, have successfully combated several ailments. Recent technological breakthroughs around novel targets, vectors, delivery systems, and adjuvants are creating new avenues for market growth. As a result, established vaccine companies are introducing higher value vaccines that are commanding significant premiums relative to traditional flu vaccines. These established players now comprise the majority of today’s vaccine industry, due to the high fixed costs associated with vaccine production. However, a host of new vaccine companies are set to enter the market space with the potential to generate similar success in areas previously not addressed by vaccines. Scientia Advisors helps clients identify the opportunities within these emerging segments of the vaccines industry. |
|
Neurostimulation Strategic Market Review Date Released: Sep 1, 2009 Neurostimulation holds potential in becoming a major treatment for neurological diseases such as Parkinson's, chronic pain, depression, epilepsy, and even migraines. With an aging population and increasing concern about efficacy and health care costs,there is a growing need for treatments that are quicker, safer, more effective and less expensive than drug-based therapies. Neurostimulation has the advantages over drug-based therapies such as being non-addictive, non-dependent on individual genetics, and no systemic side effects. By diminishing the need for ongoing medication and treatment, Neurostimulation devices could also help reduce overall health care costs.The Neurostimulation market is primarily made up of three segments: Deep Brain Stimulation (DBS), Spinal Cord Stimulation (SCS), and Sacral Nerve Stimulation (SNS). The growth of these markets is being driven by emerging companies who are developing exciting new methods and technologies for treating a variety of nerve-related disorders. The goal of this presentation is to illustrate the current state of Neurostimulation market and also to highlight some important unmet needs and key opportunities which current and potential market players must address to be successful in this market. |
|
Strategic Review of Cell Therapy Market Date Released: Dec 8, 2008 Cell Therapy promises to prevent, treat, and/or cure human diseases through the administration of ex vivo modified cells. Today, Cell Therapy is already having clinical impact in areas such as cancer and wound treatment where it is being used as the standard of care to treat some diseases. The future of the Cell Therapy market will primarily be driven by the growth of the Stem Cell segment, which itself is triggered by the forthcoming launch of novel therapies for various neurological disorders, cancer, and diabetes applications. The goal of this presentation is to illustrate the current state of Cell Therapy and also to highlight some important unmet needs and key success factors that current and potential market players must address to be successful in this market. |
|
Strategic Growth Opportunities in Functional Foods and Beverages Date Released: Dec 3, 2008 Functional Foods are foods that deliver health benefits beyond basic nutrition. The science has advanced enormously, and so has the technology to deliver these powerful nutrients within a food or beverage that still tastes good. In addition, consumers now believe that functional foods can play a role in managing their health and in the prevention of health problems. The convergence of those developments is making this an area of great excitement within the field of Health & Wellness. This presentation provides an overview of the field, gives examples of functional food ingredients as well as finished products, shows examples of successful and unsuccessful market launches, and touches on many of the components of success in this emerging industry. |
|
Impact of DNA Microarrays on Molecular Diagnostics Date Released: Oct 21, 2008 DNA microarrays are a powerful molecular diagnostic tool that facilitates multiplex, simultaneous analysis of tens to hundreds of markers that guide the identification of disease and its management. DNA microarrays have begun to move into mainstream clinical diagnostics. This presentation will review application areas of microarrays in molecular diagnostics, the market size, future growth prospects, key growth drivers, barriers, and other market forces such as regulatory and reimbursement challenges. |
|
Medical Devices: Cardiovascular Overview Date Released: Oct 6, 2008 At close to $200 B in size and growing, the Medical Device market represents one of the largest, most diverse and most robust healthcare sectors. Despite being dominated by U.S. and Western Europe markets, the worldwide medical device market is being driven by global healthcare trends such as the increase in decentralization of healthcare and increasingly obese, diabetic and elderly populations. This presentation provides a focus on cardiovascular health; traditionally one of the largest, most innovative and more competitive areas of the medical device market. |
|
Scientia Decentralization of Healthcare Presentation Date Released: Sep 18, 2008 The increasing migration of healthcare from centralized, core hospital locations to more point-of-care settings such as emergency rooms, outpatient clinics, rapid and urgent care clinics, and the home. A Decentralized Healthcare system aims to improve overall implementation of healthcare programs, provide uniformity of healthcare standards across rural and urban areas and lower costs by moving to more streamlined and efficient programs |
|
Scientia Panelists Decentralization of Healthcare Presentation Date Released: Sep 18, 2008 Presentations by: Michael Critelli - Executive Chairman of Pitney Bowes Inc., and Chairman of the Board, Dossia Alicia Ledlie - Senior Director - Health Business Development of Wal-Mart Stores Inc John Bishop - CEO, Cepheid The increasing migration of healthcare from centralized, core hospital locations to more point-of-care settings such as emergency rooms, outpatient clinics, rapid and urgent care clinics, and the home. A Decentralized Healthcare system aims to improve overall implementation of healthcare programs, provide uniformity of healthcare standards across rural and urban areas and lower costs by moving to more streamlined and efficient programs. |
|
The Future of Cancer Diagnostics Date Released: Aug 25, 2008 Cancer is a complex, multi-factorial disease comprising more than 100 similar diseases. Current diagnostic tools, including various blood marker based immuonoassays, imaging techniques, and biopsy analysis, provide valuable information but remain effective only when the tumor frequency is greater than 1% to 10%. New molecular tests such as breast cancer prognosis are changing the cancer care paradigm by providing critically needed information early in the care cycle and reducing healthcare costs. This session focuses on such high value molecular tests for solid tumors that improve disease outcome by providing early detection, prognostic information, and stratify responsiveness to therapy. |
|
Future of Healthcare - Introduction of Clay Christensen Date Released: Apr 2, 2008 This presentation briefly introduces the concepts of Clay Christensen who discusses the following: In the absence of the ability to precisely define a disease, the care of patients is best undertaken by highly skilled professionals, whose intuition is based on deep experience. This describes the history of health care, and we call this the practice of intuitive medicine. Molecular cell biology holds the promise of transforming medical practice into a new phase that we call precision medicine. It promises to dramatically reduce cost and increase the predictable effectiveness of therapy. |
|
Musculoskeletal Market Strategic Review Date Released: Mar 10, 2008 The Musculoskeletal (MSK) market is concerned with the motion and scaffold of the human body (i.e. bones, muscles, tendons, etc.) and is one of many areas of the healthcare industry poised to benefit from the developed world’s increasingly aging population. This presentation highlights the main trends and drivers of the overall MSK market and provides strategic insight into constituent sub-markets. Within the MSK market, we believe the Orthobiologics market is the most attractive segment based on market growth and lower competitive intensity. |
|
Wound Care Market Strategic Review Date Released: Feb 7, 2008 The wound care market represents an extremely diverse group of products and therapies, ranging from biological growth factors to wound therapy surfaces such as advanced hospital beds and chairs. For the most part, the wound care market has matured, however, there still remain a variety of high-growth, specialized markets that present good opportunites for investment. This presentation outlines the key drivers and trends of the overall wound care market while also providing insight into emerging trends and technologies that are being rapidly advanced by the industry’s increasing understanding and application of biological processes. |
|
Personalized Medicine Strategic Review Date Released: Dec 19, 2007 Personalized medicine tests have had a large impact on the oncology care cycle and greatly influenced therapeutic decisions. Today, as many pharmaceutical companies are plagued by fewer drug approvals and upcoming patent expirations, seeking opportunities within personalized medicine will be one way to bolster sales of therapeutics. We believe oncology therapeutics will continue to be one of the main adopters of personalized medicine and we recommend pharmaceutical companies act accordingly to strategically position themselves within the personalized medicine landscape as well as evaluate any potential influence personalized medicine might have on sales of therapeutics. The goal of this presentation is to review the various types of Molecular Diagnostic based personalized medicine tests and assess their influence on oncology patient care and oncology therapeutics. |
|
In Vitro Diagnostics Strategic Review Date Released: Dec 18, 2007 The IVD market is a modest growth market with several segments that show different growth prospects. The overall industry outlook is very positive - driven by favorable demographics, health care cost pressures, industry consolidation, and new high value products. This presentation reviews the IVD industry dynamics, key growth drivers, and market forces such as emergence of rapid clinics that will change the delivery of IVD and patient care. |
|
Molecular Diagnostics Strategic Review Date Released: Dec 17, 2007 The purpose of this presentation is to highlight the specific market segment of the in vitro diagnostics market called molecular diagnostics. This presentation includes all the accepted clinical molecular diagnostic tests worlds wide that are currently used today, and explores new tests that are on the clinical horizon. It reviews the instruments and their reagents and supplies as utilized in hospital and commercial labs, clinics, and doctors' offices on a world wide basis. |
|
Life Science Tools and Technologies Review Date Released: Dec 17, 2007 Life Science Tools and Technologies presentation has been assembled by reviewing every major life science/analytical instrument technology and major reagent in the industry. Scientia Advisors regularly reviews market sizing, growth rates, and detailed analyses for this market. |
|
Strategic Review of Point-of-Care Diagnostics Date Released: Jul 5, 2007 The purpose of this presentation is to describe the specific market segment of the in vitro diagnostics market called point of care testing (POCT). It examines these clinical measurement devices and their reagents and supplies as utilized in hospitals, clinics and doctors’ offices. An analysis of analytes that are related to the common chemical constituents of blood, plasma or serum at the point of care of the patient is addressed. Moreover, the presentation defines the dollar volume of sales, both worldwide and in the U.S., and analyzes the factors that influence the size and the growth of the market segments. Also examined are the subsections of each market segment, including the research labs, hospital labs and commercial laboratories. |
|
Challenges Posed by Combination Medical Products Date Released: Jun 22, 2007 The convergence of the biological revolution with medical devices holds the promise of a new stream of innovations. Many medical device companies are grappling with how to manage product innovation and development so as to take advantage of the biological revolution. The goal of this brief presentation is to explore the challenges and opportunities for device companies that this convergence presents. |
|
The Diabetes Circle of Care Date Released: May 24, 2007 Diabetes is the seventh-leading cause of death, and is on the rise due to increasing obesity in both developed and developing countries. Scientia's review of the diabetes market provides an overview and forecasts of the overall diabetes care life cycle and discusses the future of the diabetes circle of care. The diabetes circle of care consists of predisposition testing, diagnosis, disease treatment, monitoring, and disease management/lifestyle . This review does not cover treatment & monitoring of complications associate with diabetes and lifestyle management options associated with the disease. The review contains comprehensive details on current & emerging features in each component of the diabetes care cycle including:
|
